Abstract:We conducted a laboratory comparison trial involving 12 international laboratories to test the technical aspects of DNA methylation data generation and profile interpretation. Participants received a DNA aliquot of four low‐grade gliomas and performed the DNA methylation‐based classification and result interpretation without knowledge of histology, interpreted the copy number profiles and conducted DNA sequencing of the BRAF hotspot p.V600. Results showed a high technical reproducibility with a median pairwise correlation of 0.99 (range 0.94–0.99) between coordinating laboratory and participants. Aims DNA methylation profiling, recently endorsed by the World Health Organisation (WHO) as a pivotal diagnostic tool for brain tumours, most commonly relies on bead arrays. Despite its widespread use, limited data exist on the technical reproducibility and potential cross‐institutional differences. The LOGGIC Core BioClinical Data Bank registry conducted a prospective laboratory comparison trial with 12 international laboratories to enhance diagnostic accuracy for paediatric low‐grade gliomas, focusing on technical aspects of DNA methylation data generation and profile interpretation under clinical real‐time conditions. Methods Four representative low‐grade gliomas of distinct histologies were centrally selected, and DNA extraction was performed. Participating laboratories received a DNA aliquot and performed the DNA methylation‐based classification and result interpretation without knowledge of tumour histology. Additionally, participants were required to interpret the copy number profile derived from DNA methylation data and conduct DNA sequencing of the BRAF hotspot p.V600 due to its relevance for low‐grade gliomas. Results had to be returned within 30 days. Results High technical reproducibility was observed, with a median pairwise correlation of 0.99 (range 0.94–0.99) between coordinating laboratory and participants. DNA methylation‐based tumour classification and copy number profile interpretation were consistent across all centres, and BRAF mutation status was accurately reported for all cases. Eleven out of 12 centres successfully reported their analysis within the 30‐day timeframe. Conclusion Our study demonstrates remarkable concordance in DNA methylation profiling and profile interpretation across 12 international centres. These findings underscore the potential contribution of DNA methylation analysis to the harmonisation of brain tumour diagnostics.

DNA methylation‐array interlaboratory comparison trial demonstrates highly reproducible paediatric CNS tumour classification across 13 international centres

Analysis of gliomas DNA methylation: Assessment of pre-analytical variables

Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact

DNA methylation-based classification of central nervous system tumours

Biom-19. Methylation Profiling Of Plasma Cell-Free Dna In Pediatric Brain Tumor Patients

Machine-learning operations streamlined clinical workflows of DNA methylation-based CNS tumor classification.

Evaluating cell culture reliability in pediatric brain tumor primary cells through DNA methylation profiling

Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid

Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma

DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines

PATH-01. ACCURATE AND RAPID PAEDIATRIC BRAIN TUMOR CLASSIFICATION (PBT) BY METHYLATION PROFILING USING NOVEL NATIVE REAL TIME OXFORD NANOPORE TECHNOLOGY SEQUENCING TECHNOLOGY

DNA methylation in glioblastoma: impact on gene expression and clinical outcome

Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups

DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas

Microarray-Based DNA Methylation Profiling

Biom-66. Genome-Wide Dna Methylation Patterns In Peripheral Blood Of Patients With Glioblastoma Enrolled On The Phase Ii Vertu Trial

Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma

Epco-15. Intra-Tumoral Heterogeneity Of Dna Methylation Profiling And Cellular Composition In Glioblastoma

Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers

DNA methylation analysis with methylation‐sensitive high‐resolution melting (MS‐HRM) reveals gene panel for glioma characteristics

The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care